Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 1
1954 1
1955 2
1957 1
1964 2
1965 1
1966 2
1967 2
1970 1
1972 2
1973 4
1975 2
1976 9
1977 5
1978 6
1979 2
1981 7
1982 5
1983 4
1985 2
1986 1
1987 5
1988 4
1989 6
1990 5
1991 7
1992 3
1993 4
1994 7
1995 4
1996 5
1997 6
1998 7
1999 14
2000 14
2001 12
2002 12
2003 7
2004 19
2005 32
2006 20
2007 30
2008 36
2009 37
2010 42
2011 43
2012 41
2013 50
2014 69
2015 55
2016 53
2017 47
2018 41
2019 50
2020 63
2021 61
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

859 results
Results by year
Filters applied: . Clear all
Page 1
Gut microbiome pattern reflects healthy ageing and predicts survival in humans.
Wilmanski T, Diener C, Rappaport N, Patwardhan S, Wiedrick J, Lapidus J, Earls JC, Zimmer A, Glusman G, Robinson M, Yurkovich JT, Kado DM, Cauley JA, Zmuda J, Lane NE, Magis AT, Lovejoy JC, Hood L, Gibbons SM, Orwoll ES, Price ND. Wilmanski T, et al. Among authors: zimmer a. Nat Metab. 2021 Feb;3(2):274-286. doi: 10.1038/s42255-021-00348-0. Epub 2021 Feb 18. Nat Metab. 2021. PMID: 33619379 Free PMC article.
Update on PARP Inhibitors in Breast Cancer.
Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Zimmer AS, et al. Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2. Curr Treat Options Oncol. 2018. PMID: 29644491 Free PMC article. Review.
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM. Zimmer AS, et al. J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3. J Immunother Cancer. 2019. PMID: 31345267 Free PMC article. Clinical Trial.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Lampert EJ, et al. Among authors: zimmer a. Clin Cancer Res. 2020 Aug 15;26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. Epub 2020 May 12. Clin Cancer Res. 2020. PMID: 32398324 Free PMC article. Clinical Trial.
Babesiosis.
Zimmer AJ, Simonsen KA. Zimmer AJ, et al. 2021 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. 2021 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 28613466 Free Books & Documents.
[Neurofibromatoses].
Zimmer A. Zimmer A. Radiologe. 2013 Dec;53(12):1077-83. doi: 10.1007/s00117-013-2555-9. Radiologe. 2013. PMID: 24258315 Review. German.
Use of Protamine in Nanopharmaceuticals-A Review.
Ruseska I, Fresacher K, Petschacher C, Zimmer A. Ruseska I, et al. Among authors: zimmer a. Nanomaterials (Basel). 2021 Jun 7;11(6):1508. doi: 10.3390/nano11061508. Nanomaterials (Basel). 2021. PMID: 34200384 Free PMC article. Review.
Viral Enteritis in Solid-Organ Transplantation.
Abbas A, Zimmer AJ, Florescu D. Abbas A, et al. Among authors: zimmer aj. Viruses. 2021 Oct 7;13(10):2019. doi: 10.3390/v13102019. Viruses. 2021. PMID: 34696449 Free PMC article. Review.
859 results